公开(公告)号：US20220125806A1

公开(公告)日：2022-04-28

申请号：US17570194

申请日：2022-01-06

申请人： EIRGEN PHARMA LTD.

发明人： Jay A. White ,  Samir P. Tabash ,  Sammy A. Agudoawu ,  Joel Z. Melnick

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K47/38 ,  A61K47/44

摘要： A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

公开(公告)号：US20210260079A1

公开(公告)日：2021-08-26

申请号：US17317823

申请日：2021-05-11

申请人： EIRGEN PHARMA LTD.

发明人： P. Martin Petkovich ,  Joel Z. Melnick ,  Jay A. White ,  Samir P. Tabash ,  Charles W. Bishop ,  Susan Peers ,  Stephen A. Strugnell

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/00 ,  A61K47/26 ,  A61K9/48 ,  A61K31/675 ,  A61K39/395 ,  A61K31/135 ,  A61K31/663 ,  A61K47/44 ,  A61K31/137 ,  A61K45/06 ,  A61K47/06 ,  A61K47/14 ,  A61K47/38

摘要： Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

公开(公告)号：US20230346804A1

公开(公告)日：2023-11-02

申请号：US18141805

申请日：2023-05-01

申请人： EIRGEN PHARMA LTD

发明人： Eric J. Messner ,  P. Martin Petkovich ,  Jay A. White ,  Samir P. Tabash ,  Joel Z. Melnick ,  Charles W. Bishop

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/48

CPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/4858

摘要： Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxyvitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxyvitamin D.

公开(公告)号：US11738033B2

公开(公告)日：2023-08-29

申请号：US17317823

申请日：2021-05-11

申请人： EIRGEN PHARMA LTD.

发明人： P. Martin Petkovich ,  Joel Z. Melnick ,  Jay A. White ,  Samir P. Tabash ,  Charles W. Bishop ,  Susan Peers ,  Stephen A. Strugnell

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/00 ,  A61K47/26 ,  A61K9/48 ,  A61K31/675 ,  A61K39/395 ,  A61K31/135 ,  A61K31/663 ,  A61K47/44 ,  A61K31/137 ,  A61K45/06 ,  A61K47/06 ,  A61K47/14 ,  A61K47/38 ,  A61K39/00

CPC分类号： A61K31/593 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4875 ,  A61K31/135 ,  A61K31/137 ,  A61K31/592 ,  A61K31/663 ,  A61K31/675 ,  A61K39/395 ,  A61K45/06 ,  A61K47/06 ,  A61K47/14 ,  A61K47/26 ,  A61K47/38 ,  A61K47/44 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  A61K31/663 ,  A61K2300/00 ,  A61K31/593 ,  A61K2300/00 ,  A61K31/592 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00 ,  A61K39/395 ,  A61K2300/00 ,  A61K31/675 ,  A61K2300/00 ,  A61K31/675 ,  A61L2300/00

摘要： Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.